GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...

"GSK today announced that it has reached agreements with 10 plaintiff firms who together represent 93 percent (approximately 80,000) of the Zantac state ... non-commercial name ranitidine, was ...

As well as being sold by GSK, the drug has also been marketed by other major pharmaceutical ... A drug under the name of Zantac 360, which contains no ranidine, is still being currently sold.

GSK said: “While the scientific consensus remains that there is no consistent or reliable evidence that ranitidine [the generic name for Zantac] increases ... GSK and other sellers of the ...

By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a ...